ArticleNucleic acids research2026
Automated high-throughput selection of DNA aptamers using a common optical next-generation sequencer.
Article in Nucleic acids research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Aptamers are conventionally selected via 'Systematic Evolution of Ligands by Exponential Enrichment' (SELEX). However, this process is laborious, time-consuming, and has a relatively low efficacy. In this study, we present a novel automated high-throughput screening platform that augments the conventional selection of DNA aptamers. To this end, the software of an optical next-generation sequencer has been modified to automatically perform fluorescence-based binding assays on the displayed DNA sequences subsequent to sequencing. Utilizing this platform, high-affinity DNA aptamers were identified for the proteins LecA, LecB, and Pseudomonas Exotoxin A (PEA) of Pseudomonas aeruginosa following pre-enrichment by a mere three to five SELEX rounds. Conversely, 12 rounds of conventional SELEX yielded aptamers exhibiting three-fold lower affinity for LecA and PEA, with no aptamers obtained for LecB. Furthermore, we demonstrate that the proposed method is suitable for the study of molecules ranging from small molecules to whole cells. This is evidenced by a mutation assay for a kanamycin-binding aptamer and the monitoring of Escherichia coli binding to aptamers. The present study proposes a high-throughput approach to enhance SELEX, with the potential to provide greater insight into the selection process and to significantly increase efficacy, enabling the selection of aptamers within a week.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.